Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Nanobiotix S.A.
Nanobiotix S.A. News
Nanobiotix S.A. Quantitative Score
About Nanobiotix S.A.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Nanobiotix S.A. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Nanobiotix S.A. Financials
Table Compare
Compare NBTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | NBTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | NBTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | NBTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | NBTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Nanobiotix S.A. Income
Nanobiotix S.A. Balance Sheet
Nanobiotix S.A. Cash Flow
Nanobiotix S.A. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Nanobiotix S.A. Executives
| Name | Role |
|---|---|
| Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer |
| Louis Kayitalire | Chief Medical Officer & Member of Executive Board |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board |
| Anne-Juliette Hermant | Chief People Officer & Member of Executive Board |
| Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Laurent Levy | Co-Founder, President of the Executive Board & Chief Executive Officer | Male | 1973 | 887.69K |
| Louis Kayitalire | Chief Medical Officer & Member of Executive Board | 1958 | 706.27K | |
| Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | Male | 1973 | 704.49K |
| Anne-Juliette Hermant | Chief People Officer & Member of Executive Board | Female | 1974 | 442.49K |
| Leonard A. Farber | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | -- |